Kounnas M Z, Henkin J, Argraves W S, Strickland D K
Biochemistry Laboratory, American Red Cross, Rockville, Maryland 20855.
J Biol Chem. 1993 Oct 15;268(29):21862-7.
The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. Previous work has shown that LRP is responsible for mediating the internalization of urinary-type plasminogen activator (uPA) complexed to plasminogen activator inhibitor type I (PAI-1) (Nykjaer et al., 1992; Herz et al., 1992). The current study indicates that pro-urokinase (pro-uPA) and two chain urokinase (tc-uPA) bind directly to purified LRP, and that LRP mediates their internalization and degradation in Hep G2 cells. In vitro binding assays demonstrated that pro-uPA and tc-uPA bind to purified LRP with affinities (Kd = 45 and 60 nM, respectively) that are approximately 15 to 20-fold weaker than the affinity of uPA.PAI-1 complex for LRP (Kd = 3 nM). Competitive binding experiments revealed that pro-uPA and tc-uPA completely inhibit binding of uPA.PAI-1 complexes to purified LRP. The binding of 125I-pro-uPA to LRP is blocked by the 39-kDa receptor-associated protein, but not by an amino-terminal fragment of uPA, which is known to block binding of uPA to the urokinase receptor. 125I-Pro-uPA can be internalized and degraded by Hep G2 cells independent of PAI-1. Both the internalization and degradation are completely blocked by receptor-associated protein or affinity-purified LRP antibodies, indicating that LRP is mediating this process. These processes are also blocked by the amino-terminal fragment, which suggests that the favored pathway for uPA metabolism is initial binding to the urokinase receptor, followed by ligand transfer to LRP, then internalization leading to degradation.
低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体(LRP)是一种大型细胞表面受体,由一条515 kDa的重链和一条85 kDa的轻链组成,轻链是从600 kDa的前体经蛋白水解衍生而来。先前的研究表明,LRP负责介导与I型纤溶酶原激活物抑制剂(PAI-1)复合的尿激酶型纤溶酶原激活物(uPA)的内化(尼耶尔等人,1992年;赫茨等人,1992年)。当前研究表明,单链尿激酶型纤溶酶原激活物(pro-uPA)和双链尿激酶(tc-uPA)直接结合纯化的LRP,并且LRP介导它们在肝癌细胞系(Hep G2)中的内化和降解。体外结合试验表明,pro-uPA和tc-uPA与纯化的LRP结合,其亲和力(解离常数分别为45和60 nM)比uPA-PAI-1复合物与LRP的亲和力(解离常数=3 nM)弱约15至20倍。竞争性结合实验表明,pro-uPA和tc-uPA完全抑制uPA-PAI-1复合物与纯化的LRP的结合。125I-pro-uPA与LRP的结合被39 kDa的受体相关蛋白阻断,但不被已知可阻断uPA与尿激酶受体结合的uPA氨基末端片段阻断。125I-pro-uPA可被Hep G2细胞内化和降解,且不依赖于PAI-1。内化和降解均被受体相关蛋白或亲和纯化的LRP抗体完全阻断,表明LRP介导了这一过程。这些过程也被氨基末端片段阻断,这表明uPA代谢的有利途径是首先与尿激酶受体结合,然后配体转移至LRP,接着内化导致降解。